Acadian Asset Management LLC lowered its position in Humana Inc (NYSE:HUM) by 2.4% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,292,700 shares of the insurance provider’s stock after selling 31,981 shares during the period. Humana comprises about 1.8% of Acadian Asset Management LLC’s portfolio, making the stock its 8th largest position. Acadian Asset Management LLC owned about 0.94% of Humana worth $437,604,000 at the end of the most recent reporting period.
Several other hedge funds have also recently made changes to their positions in HUM. FMR LLC raised its holdings in shares of Humana by 12.7% in the second quarter. FMR LLC now owns 12,212,514 shares of the insurance provider’s stock valued at $3,634,811,000 after purchasing an additional 1,374,030 shares during the last quarter. Glenmede Trust Co. NA increased its holdings in Humana by 153.7% during the second quarter. Glenmede Trust Co. NA now owns 500,266 shares of the insurance provider’s stock worth $148,895,000 after buying an additional 303,080 shares during the last quarter. Unigestion Holding SA purchased a new stake in Humana during the second quarter worth about $79,340,000. LFA Lugano Financial Advisors SA purchased a new stake in Humana during the second quarter worth about $204,000. Finally, Bank of Montreal Can increased its holdings in Humana by 61.7% during the second quarter. Bank of Montreal Can now owns 413,429 shares of the insurance provider’s stock worth $123,049,000 after buying an additional 157,752 shares during the last quarter. Institutional investors own 93.05% of the company’s stock.
In other Humana news, insider Roy A. Beveridge sold 4,622 shares of Humana stock in a transaction that occurred on Thursday, November 8th. The shares were sold at an average price of $341.06, for a total transaction of $1,576,379.32. Following the completion of the sale, the insider now directly owns 10,621 shares in the company, valued at $3,622,398.26. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Bruce D. Broussard sold 18,000 shares of Humana stock in a transaction that occurred on Monday, September 10th. The shares were sold at an average price of $328.66, for a total transaction of $5,915,880.00. Following the sale, the chief executive officer now owns 71,085 shares of the company’s stock, valued at $23,362,796.10. The disclosure for this sale can be found here. Insiders own 0.60% of the company’s stock.
HUM has been the subject of a number of research analyst reports. Zacks Investment Research upgraded shares of Humana from a “hold” rating to a “buy” rating and set a $377.00 price objective for the company in a report on Thursday, October 4th. Morgan Stanley raised their price objective on shares of Humana from $400.00 to $418.00 and gave the stock a “buy” rating in a report on Thursday, November 8th. Credit Suisse Group raised their price objective on shares of Humana from $350.00 to $370.00 and gave the stock an “outperform” rating in a report on Tuesday, September 4th. Piper Jaffray Companies restated a “buy” rating and set a $355.00 price objective on shares of Humana in a report on Thursday, August 2nd. Finally, Cowen initiated coverage on shares of Humana in a report on Monday, September 17th. They set a “market perform” rating and a $372.00 price objective for the company. Seven investment analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $352.30.
Shares of HUM stock traded down $2.12 during trading hours on Thursday, reaching $305.10. The stock had a trading volume of 1,414,273 shares, compared to its average volume of 913,885. The company has a current ratio of 1.68, a quick ratio of 1.68 and a debt-to-equity ratio of 0.45. Humana Inc has a 12 month low of $235.56 and a 12 month high of $355.88. The firm has a market capitalization of $42.15 billion, a P/E ratio of 26.05, a price-to-earnings-growth ratio of 1.46 and a beta of 1.03.
Humana (NYSE:HUM) last released its quarterly earnings data on Wednesday, November 7th. The insurance provider reported $4.58 EPS for the quarter, beating analysts’ consensus estimates of $4.29 by $0.29. Humana had a net margin of 2.70% and a return on equity of 19.10%. The company had revenue of $14.21 billion during the quarter, compared to analyst estimates of $13.97 billion. During the same period last year, the business earned $3.39 earnings per share. Sell-side analysts predict that Humana Inc will post 14.43 EPS for the current year.
The business also recently announced a quarterly dividend, which will be paid on Friday, January 25th. Shareholders of record on Monday, December 31st will be given a dividend of $0.50 per share. The ex-dividend date of this dividend is Friday, December 28th. This represents a $2.00 annualized dividend and a yield of 0.66%. Humana’s payout ratio is presently 17.08%.
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company operates through four segments: Retail; Group and Specialty; Healthcare Services; and Individual Commercial. The Retail segment offers Medicare and supplemental benefit plans to individuals or through group accounts.
Read More: What is a stock buyback?
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.